Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Rises By 521.0%

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 352,700 shares, a growth of 521.0% from the July 15th total of 56,800 shares. Currently, 6.6% of the company’s shares are sold short. Based on an average daily trading volume, of 700,600 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a research note on Monday, July 22nd.

Hoth Therapeutics Stock Performance

Shares of HOTH traded up $0.01 during mid-day trading on Monday, reaching $0.62. The stock had a trading volume of 59,274 shares, compared to its average volume of 501,682. The business has a fifty day moving average of $0.88 and a 200 day moving average of $1.14. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.37. The firm has a market cap of $3.34 million, a price-to-earnings ratio of -0.32 and a beta of 0.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Tuesday, May 14th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). On average, research analysts forecast that Hoth Therapeutics will post -1.4 EPS for the current fiscal year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.